OAM
SER icon

Oxford Asset Management’s Serina Therapeutics SER Stock Holding History

Oxford Asset Management’s Portfolio SER Stock Details SER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-648
Closed -$41K – 1359
2019
Q4 		$41K Sell
648
-22
-3% -$1.19K ﹤0.01% 1674
2019
Q3 		$46K Buy
670
+90
+16% +$8.54K ﹤0.01% 1657
2019
Q2 		$75K Buy
+580
New +$78.5K ﹤0.01% 1624

Other funds holding SER

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Oxford Asset Management's SER Position: Q1 2020 in Review

Oxford Asset Management sold out of Serina Therapeutics (SER) in Q1 2020, closing a stake of 648 shares — an estimated $41K sold.

Oxford Asset Management first reported a position in SER in Q2 2019 and held it in 3 quarters. The position peaked at $75K in Q2 2019. 49 funds tracked by Wall St. Rank hold SER as of Q1 2020.

  • Oxford Asset Management reported no remaining Serina Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 648 Serina Therapeutics shares in Q1 2020, an estimated $41K.
  • Oxford Asset Management first reported a position in Serina Therapeutics in Q2 2019 and held it in 3 quarters.
  • Oxford Asset Management's Serina Therapeutics position peaked at $75K in Q2 2019.
  • 49 funds tracked by Wall St. Rank held Serina Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.